Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05983939 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers
A Phase 1 study, sponsored by Contineum Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT05983939 is a Phase 1 study that has completed, run by Contineum Therapeutics. The registered enrollment target is 56 participants.
The verdict
NCT05983939, a Phase 1 study, has completed, sponsored by Contineum Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This study will be conducted in three parts: Part 1 will be a Single Ascending Dose (SAD), Part 2 will be a Multiple Ascending Dose (MAD), and Part 3 will be a selected SAD cohort in a fed state. Safety will be assessed by periodic measurement of vital signs, physical examinations, electrocardiograms, blood laboratory analyses and occurrence of adverse events (AE).
Interventions
- DRUG Placebo
- DRUG PIPE-791
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2023-06-26 |
| Est. Completion | 2024-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05983939
The ClinicalTrials.gov registry entry for NCT05983939 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Contineum Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05983939 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05983939 about?
NCT05983939 is a clinical study titled "Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers". This study will be conducted in three parts: Part 1 will be a Single Ascending Dose (SAD), Part 2 will be a Multiple Ascending Dose (MAD), and Part 3 will be a selected SAD cohort in a fed state. Safety will be assessed by periodic measurement of vital signs, physical examinations, electrocardiogram...
What is the current status of trial NCT05983939?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2023-06-26. Estimated completion is 2024-02-01.
What interventions are being tested in trial NCT05983939?
The interventions under investigation include: Placebo (DRUG), PIPE-791 (DRUG).
Who is sponsoring clinical trial NCT05983939?
This trial is sponsored by Contineum Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.